adalimumab-atto (Amjevita) vs infliximab-qbtx (Ixifi)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-atto (Amjevita)
Marketed by Amgen
NCT01970475 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).
Reported efficacy
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)
Result source: NCT01970475
infliximab-qbtx (Ixifi)
Marketed by Pfizer
NCT02222493 · Phase 3 · completed
This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.
Reported efficacy
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) (met)
Result source: NCT02222493
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-atto (Amjevita) | infliximab-qbtx (Ixifi) |
|---|---|---|
| ACR20 | 74.6% vs 72.4%vs AdalimumabNCT019704752 other results
| 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT0222249312 other results
|
| ACR50 | 49.2% vs 52%vs AdalimumabNCT01970475 | —Not reported |
| ACR70 | 26% vs 22.9%vs AdalimumabNCT01970475 | —Not reported |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | —Not reported | —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-atto (Amjevita)
- 74.6% vs 72.4%vs AdalimumabNCT01970475
2 other results
- 35.4% vs 24.5% NCT01970475
- 63.5% vs 62.5% NCT01970475
- infliximab-qbtx (Ixifi)
- 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT02222493
12 other results
- 32.4% vs 37.1% NCT02222493
- 52.5% vs 58.3% NCT02222493
- 57.7% vs 61.7% NCT02222493
- 64.8% vs 65.6% NCT02222493
- 63.3% vs 65.3% NCT02222493
- 60.8% vs 64.1% NCT02222493
- 73.6% vs 70.6% NCT02222493
- 76.9% vs 70.6% NCT02222493
- 71.1% vs 68.5% NCT02222493
- 69.2% vs 68.5% NCT02222493
- 71.1% vs 64.3% NCT02222493
- 70.6% vs 64.3% NCT02222493
ACR50
- adalimumab-atto (Amjevita)
- 49.2% vs 52%vs AdalimumabNCT01970475
- infliximab-qbtx (Ixifi)
- —Not reported
ACR70
- adalimumab-atto (Amjevita)
- 26% vs 22.9%vs AdalimumabNCT01970475
- infliximab-qbtx (Ixifi)
- —Not reported
DAS28-CRP remission
- adalimumab-atto (Amjevita)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
HAQ-DI, change
- adalimumab-atto (Amjevita)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
Modified Sharp score, change
- adalimumab-atto (Amjevita)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-atto (Amjevita): 4 of 4 rows · infliximab-qbtx (Ixifi): 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-atto (Amjevita) | infliximab-qbtx (Ixifi) |
|---|---|---|
| Dropout rate | 8%a NCT01970475 · Phase 3 | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | 2.7%a NCT01970475 · Phase 3 | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Serious AEs | 3.8%a NCT01970475 · Phase 3 | 5%Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results2.8%Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.6%Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 2.4%Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.8%Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.2%Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | alanine aminotransferase increased 5.9% infusion related reaction 5.9% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more resultsinfusion related reaction 4.2% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 infusion related reaction 2.9% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-atto (Amjevita)
show 5 more results
infliximab-qbtx (Ixifi)
show 8 more results
+ 41 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-atto (Amjevita)'s landscape · infliximab-qbtx (Ixifi)'s landscape